WO2003070279A1 - Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient - Google Patents
Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient Download PDFInfo
- Publication number
- WO2003070279A1 WO2003070279A1 PCT/EP2003/001650 EP0301650W WO03070279A1 WO 2003070279 A1 WO2003070279 A1 WO 2003070279A1 EP 0301650 W EP0301650 W EP 0301650W WO 03070279 A1 WO03070279 A1 WO 03070279A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- pde
- inhibitor
- halogen
- pvp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the field of pharmaceutical technology and describes a dosage form for oral administration of a PDE 4 inhibitor as active ingredient in tablet or pellet form for treating diseases such as asthma or airway obstructions.
- the invention additionally relates to processes for producing the dosage form.
- PDE Cyclic nucleotide phosphodiesterase
- WO00/50011 and WO01/32165 which relate to dosage forms with controlled or sustained delivery of a PDE 4 inhibitor, it is pointed out that unwanted CNS side effects may become manifest on delivery of certain PDE 4 inhibitors such as Ariflo® (INN: cilomilast) in higher dosages.
- PDE 4 inhibitors such as Ariflo® (INN: cilomilast) in higher dosages.
- WO00/50011 and WO01/32165 see this as being a particular risk with immediate release dosage forms of the active ingredient and therefore propose administering the PDE 4 inhibitor Ariflo® (INN: cilomilast) in dosage forms with controlled or sustained release.
- US 5,286,494 proposes a dosage form with controlled or sustained release for the PDE 4 inhibitor Rolipram whose solubility is slight.
- production of dosage forms with controlled or sustained release of slightly soluble active ingredients may be technically complicated, reference being made thereto for example in US 5,286,494.
- the solubility of active ingredients of the PDE 4 inhibitor class in water and aqueous systems may, depending on the chemical structure, be low.
- the solubility in water found for the PDE 4 inhibitor N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (INN: roflumilast) which is described in WO95/01338, is only 0.53 mg/i at 21 °C.
- the bioavailability of a medicinal substance depends essentially on the release of the medicinal substance from the pharmaceutical form. Faster release and dissolution of the medicinal substance from the formulation means faster absorption thereof. With medicinal substances which are slightly soluble in water, therefore, the bioavailability is frequently limited by the solubility or rate of dissolution. This makes it very difficult to produce suitable dosage forms. Description of the invention
- the oral dosage form of the invention is preferably a solid dosage form in tablet or pellet form. It is preferably a solid oral dosage form with immediate release of the active ingredient (immediate release solid oral dosage form).
- the invention therefore relates to a dosage form in tablet or pellet form for oral administration of a PDE 4 inhibitor whose solubility is slight, comprising the PDE 4 inhibitor whose solubility is slight together with polyvinylpyrrolidone as binder, and one or more other suitable pharmaceutical excipients.
- the PDE 4 inhibitor whose solubility is slight is preferably according to the invention a compound from the group of compounds of the formula I
- R1 is 3-7C cycloalkoxy, 3-7C cycloalkylmethoxy or benzyloxy and
- R2 is 1 -4C alkoxy which is completely or partly substituted by fluorine, T EP03/01650
- R1 is 1-4C alkoxy which is completely or partly substituted by fluorine and
- R2 is 3-7C oycloalkylmethoxy or benzyloxy
- R3 is phenyl, pyridyl, phenyl substituted by R31 , R32 and R33, or pyridyl substituted by R34, R35,
- R31 is hydroxyl, halogen, cyano, carboxyl, trifluoromethyl, 1-4C alkyl, 1-4C alkoxy, 1-40 alkoxy- carbonyl, 1-40 alkylcarbonyl, 1-4C alkylcarbonyloxy, amino, mono- or di-1-4C alkylamino or 1-4C alkylcarbonylamino,
- R32 is hydrogen, hydroxyl, halogen, amino, trifluoromethyl, 1-4C alkyl or 1-4C alkoxy,
- R33 is hydrogen, halogen, 1-4C alkyl or 1-4C alkoxy
- R34 is hydroxyl, halogen, cyano, carboxyl, 1-4C alkyl, 1-4C alkoxy, 1-4C alkoxycarbonyl or amino,
- R35 is hydrogen, halogen, amino or 1-4C alkyl
- R36 is hydrogen or halogen
- R37 is hydrogen or halogen, the salts of these compounds and the N-oxides of the pyridines and the salts thereof.
- Cycloalkoxy is, for example, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and cycloheptyloxy, of which cyclopropyloxy, cyclobutyloxy and cyclopentyloxy are preferred.
- Oycloalkylmethoxy is, for example, cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy and cycloheptylmethoxy, of which cyclopropylmethoxy, cyclobutylmethoxy and cyclopentylmethoxy are preferred.
- Examples which may be mentioned of 1-40 alkoxy which is completely or partly substituted by fluorine are 1 ,2,2-trifluoroethoxy, 2,2,3,3,3-pentafluoropropoxy, perfluoroethoxy and, in particular, 1 ,1 ,2,2-tetra- fluoroethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy and difluoromethoxy radicals.
- Halogen for the purposes of the present invention is bromine, chlorine and fluorine.
- Alkyl represents straight-chain or branched alkyl radicals having 1 to 4 carbon atoms. Examples which may be mentioned are butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl, ethyl and methyl radicals.
- 1-4C Alkoxy is a radical which, besides the oxygen atom, contains one of the aforementioned 1-4C alkyl radicals. Examples which may be mentioned are the methoxy and ethoxy radicals.
- 1-4C Alkoxycarbonyl is a carbonyl group to which one of the aforementioned 1-4C alkoxy radicals is bonded. Examples which may be mentioned are the methoxycarbonyl (CH3O-CO-) and ethoxycarbonyl (CH3CH2O-CO-) radicals.
- 1-4C Alkylcarbonyl is a carbonyl group to which one of the aforementioned 1-4C alkyl radicals is bonded.
- An example which may be mentioned is the acetyl radical (CH3CO-).
- Alkylcarbonyloxy radicals comprise besides the oxygen atom one of the aforementioned
- Examples of mono- or di-1-4C alkylamino radicals which may be mentioned are the methylamino, dimethylamino and diethylamino radicals.
- a 1-4C alkyicarbonylamino radical which may be mentioned is the acetylamino radical (-NH-CO-CH3).
- phenyl radicals substituted by R31 , R32 and R33 which may be mentioned are the radicals 2-acetyl phenyl, 2-aminophenyl, 2-bromophenyl, 2-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 4-diethylamino-2-methylphenyl, 4-bromo-2-trifluoromethylphenyl, 2-carboxy- 5-chlorophenyl, 3,5-dichloro-2-hydroxyphenyl, 2-bromo-4-carboxy-5-hydroxyphenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 2,4,6-trichlorophenyl, 2,4,6-trifluorophenyl, 2,6-dibromophenyl, 2-cyanophenyl, 4-cyano-2-fluorophenyl, 2-fluorophenyl, 2,4-difluorophenyl, 2,6-d
- pyridyl radicals substituted by R34, R35, R36 and R37 which may be mentioned are the radicals 3,5-dichloropyrid-4-yl, 2,6-diaminopyrid-3-yl, 4-aminopyrid-3-yl, 3-methylpyrid-2-yl, 4-methylpyrid-2-yl, 5-hydroxypyrid-2-yl, 4-chloropyrid-3-yl, 3-chloropyrid-2-yl, 3-chloropyrid-4-yl, 2-chloropyrid-3-yl, 2,3,5,6-tetrafluoropyrid-4-yl, 3,5-dichloro-2,6-difluoropyrid-4-yl, 3,5-dibromopyrid- 2-yl, 3,5-dibromopyrid-4-yl, 3,5-dichloropyrid-3-yl, 3,5-dii
- Salts suitable for compounds of the formula I - depending on the substitution - are all acid addition salts but, in particular, all salts with bases. Particular mention may be made of the pharmacologically acceptable salts of the inorganic and organic acids and bases normally used in pharmaceutical technology. Pharmacologically unacceptable salts which, for example, may be the initial products of the process for preparing the compounds of the invention on the industrial scale are converted into pharmacologically acceptable salts by processes known to the skilled worker.
- water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid, or 3-hydroxy-2-naphthoic acid, the acids being employed to prepare the salts in the equimolar ratio of amounts, or one differing therefrom - depending on whether the acid is monobasic or polybasic and depending on which salt is desired.
- acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, ni
- salts with bases are also particularly suitable.
- basic salts which may be mentioned are lithium, sodium, potassium, calcium, aluminum, magnesium, titanium, ammonium, meglumine or guanidinium salts, once again the bases being employed to prepare the salts in the equimolar ratio of amounts or one differeing therefrom.
- R1 is 3-5C cycloalkoxy, 3-5C cycloalkylmethoxy or benzyloxy and
- R2 is 1 -4C alkoxy which is completely or partly substituted by fluorine, or
- R1 is 1-4C alkoxy which is completely or partly substituted by fluorine and
- R2 is 3-5C cycloalkylmethoxy or benzyloxy
- R3 is phenyl, pyridyl, phenyl substituted by R31 , R32 and R33, or pyridyl substituted by R34, R35,
- R31 is halogen, cyano, carboxyl, 1-4C alkyl, 1-4C alkoxy or 1-4C alkoxycarbonyl,
- R32 is hydrogen, halogen, 1-4C alkyl or 1-4C alkoxy
- R33 is hydrogen, halogen, 1-4C alkyl or 1-4C alkoxy
- R34 is halogen or 1 -40 alkyl
- R35 is hydrogen or halogen
- R36 is hydrogen or halogen
- R37 is hydrogen or halogen, . the salts of these compounds, and the N-oxides of the pyridines and salts thereof.
- R1 is 3-5C cycloalkoxy, 3-5C cycloalkylmethoxy or benzyloxy and
- R2 is 1 -40 alkoxy which is completely or partly substituted by fluorine, or
- R1 is 1 -40 alkoxy which is completely or partly substituted by fluorine and P T/EP03/01650
- R2 is 3-5C cycloalkylmethoxy or benzyloxy
- R3 is 2-bromophenyl, 2,6-dichloro-4-ethoxycarbonylphenyl, 2,6-dimethoxyphenyl, 4-cyano-2-fluoro- phenyl, 2,4,6-trifluorophenyl, 2-chloro-6-methylphenyl, 2,6-dimethylphenyl, 2,6-difluorophenyl, 2,6-dichlorophenyl, 3,5-dichloropyrid-4-yl, 3-methylpyrid-2-yl, 2-chloropyrid-3-yl, 3,5-dibromopyrid- 2-yl, 2,3,5,6-tetrafluoropyrid-4-yl, 3-chloro-2,5,6-trifluoropyrid-4-yl, 3,5-dichloro-2,6-difluoropyrid- 4-yl or 2,6-dichloropyrid-3-yl, the salts of these compounds, and the N-oxides of the
- Preferred compounds of the formula I are those in which
- R1 is difluoromethoxy
- R2 is cyclopropylmethoxy
- R3 is 2-bromophenyl, 2,6-dichloro-4-ethoxycarbonylphenyl, 2,6-dimethoxyphenyl, 4-cyano-
- a particularly preferred compound of the formula I is the one in which
- R1 is difluoromethoxy
- R2 is cyclopropylmethoxy
- R3 is 3,5-dichloropyrid-4-yl, the salts of these compounds, and the N-oxide of the pyridine and salts thereof.
- This compound has the chemical name N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy- 4-difluoromethoxybenzamide (INN: roflumilast).
- the PDE 4 inhibitor whose solubility is slight is preferably a PDE 4 inhibitor with a solubility in water of less than or equal to 100 milligram/liter, particularly preferably with a solubility in water of less than or equal to 1 milligram/liter, at a temperature of 15 to 25°C, in particular at 21 °C.
- This compound is particularly preferably one of the formula I.
- suitable pharmaceutical excipients which may be used in the dosage form of the invention are pharmaceutical excipients such as fillers, additional binders, tablet disintegrants or else lubricants and release agents.
- suitable excipients which may be present in the dosage form of the invention are, for example, flavoring substances (such as flavors and sweeteners), buffer substances, preservatives, coloring substances (such as iron oxid yellow or red) or else emulsifiers.
- Flavors are usually added in a proportion of from 0.05 to 1 % by weight.
- Other flavoring substances by way of example are acids such as citric acid, sweeteners such as saccharin, aspartame, cyclamate sodium or maltol, which are added according to the desired result.
- the polyvinylpyrrolidone (PVP) employed according to the invention is, in particular, a water-soluble PVP (PVP)
- PVP with an average molecular weight above 2 000, preferably above 20 000.
- Examples which may be mentioned are Kollidon 12 PF (molecular weight 2 000-3 000), Kollidon 17 PF (molecular weight
- Kollidon 90 F molecular weight 1 000000-1 500 000.
- PVP of higher molecular weight such as, for example, Kollidon 25, Kollidon 30 and Kollidon 90 F may be mentioned as preferred.
- PVP polyvinyl acetate
- gelatin e.g. Kollidon® VA 64
- corn starch mucilage e.g. corn starch mucilage
- preswollen starches Starch 1500
- HPMC hydroxypropyl- methylcellulose
- L-HPC hydroxypropylcellulose
- Fillers suitable according to the invention are fillers such as calcium carbonate (e.g. MagGran® CO or Destab® 95) and sodium carbonate, sugar alcohols such as mannitol (e.g. Perlitol® or Parteck® M), sorbitol (e.g. Karion®), xylitol or maltitol, starches such as corn starch, potato starch and wheat starch, microcrystalline cellulose, saccharides such as glucose, lactose (e.g. lactose monohydrate), levulose, sucrose and dextrose. It is also possible if desired to use mixtures thereof. Corn starch, microcrystalline cellulose and lactose may be mentioned as preferred.
- sugar alcohols such as mannitol (e.g. Perlitol® or Parteck® M), sorbitol (e.g. Karion®), xylitol or maltitol
- starches such as corn starch, potato starch and wheat starch
- Suitable lubricants and release agents which may be mentioned are sodium stearyl fumarate, magnesium stearate, calcium stearate, stearic acid, talc and colloidal anhydrous silica (Aerosil).
- insoluble polyvinylpyrrolidone insoluble PVP, crospovidone
- carboxymethylstarch sodium sodium starch glycolate
- sodium carboxymethylcellulose e.g. Starch 1500
- starches able to carry out the function of a disintegrant e.g. Starch 1500.
- the proportion (in percent by weight based on the finished dosage form) of PDE 4 inhibitor in the dosage form of the invention is usually, depending on the nature of the PDE 4 inhibitor, from 0.01 to 50% by weight.
- the proportion of PDE 4 inhibitor is preferably up to 20% by weight.
- the proportion (in percent by weight based on the finished dosage form) of binder (PVP and, where appropriate, other binders) may preferably be according to the invention from 0.5 to 20% by weight.
- the proportion of PVP is preferably from 1 to 5% by weight, particularly preferably 2 to 3% by weight.
- the proportion (in percent by weight based on the finished dosage form) of filler in the tablet of the invention is advantageously from 40 to 99% by weight.
- the proportion of filler is preferably from 60 to 97% by weight.
- the proportion (in percent by weight based on the finished dosage form) of disintegrant in the rapidly disintegrating tablet can usually be up to 35% by weight.
- the proportion of disintegrant is preferably from 2 to 20% by weight.
- the proportion of disintegrant is particularly preferably from 5 to 10% by weight.
- the proportion (in percent by weight based on the finished dosage form) of lubricant or release agent in the rapidly disintegrating tablet is usually from 0.1 to 5% by weight.
- the proportion of lubricant or release agent is preferably from 0.3 to 3% by weight.
- the proportion of lubricant or release agent is particularly preferably from 0.5 to 2% by weight.
- the dosage form is a tablet. It is preferred for the tablet, besides the PDE 4 inhibitor whose solubility is slight and PVP, to comprise as further pharmaceutical excipients at least one filler and at least one lubricant or release agent.
- the pharmaceutical preparation of the invention can be produced by processes known to the skilled worker for producing tablets and pellets.
- the pharmaceutical form of the invention is produced by producing a solid solution of the PDE 4 inhibitor whose solubility is slight in the binder PVP as carrier.
- This can take place for example by the solvent method in which PVP, the PDE 4 inhibitor and, where appropriate, other pharmaceutical excipients are dissolved in a suitable solvent, and the solvent is subsequently removed again by spray drying, normal drying, vacuum drying or freeze-drying. It has been found, surprisingly, that production of the solid solution is also possible by the mixing method in which a PDE 4 inhibitor whose solubility is slight and, where appropriate, other pharmaceutical excipients are vigorously mixed together with PVP.
- the invention also relates further to a solid solution of a PDE 4 inhibitor whose solubility is slight in the binder PVP as carrier.
- a solid solution of the PDE 4 inhibitor in the binder PVP as carrier means according to the invention a solid solution with amorphous structure in which the PDE 4 inhibitor is in the form of a molecular dispersion in the carrier material.
- the solid solution may be processed as active ingredient component together with the filler, binder, disintegrant and lubricant components by production processes familiar to the skilled worker to give the oral dosage forms of the invention.
- the invention therefore also relates to a process for producing a dosage form in tablet or pellet form for oral administration of a PDE 4 inhibitor, comprising the steps: (a) production of an active ingredient preparation in the form of a solid solution in PVP of the PDE 4 inhibitor whose solubility is slight,
- the granules obtained in (c) can, after drying and mixing with lubricants or release agents, be compressed in a tablet press.
- the wet granules obtained in (c) can be processed by the extruder/spheroidizer process to suitable pellets.
- dispersions/suspensions of an active ingredient preparation can be applied in the form of a solid solution in PVP of the PDE 4 inhibitor whose solubility is slight in a suitable solvent to pellet-like carriers (e.g. nonpareils or HPMC-containing pellets).
- the dosage form of the invention is produced by granulating a mixture of active ingredient and pharmaceutical excipients with an aqueous PVP solution, drying the granules and, if desired, admixing other pharmaceutical excipients. Wet preparations obtained after granulation can then be further processed to pellets and can subsequently be packed into capsules. Dried granules can - if desired after admixture of other pharmaceutical excipients - after mixing with a release agent be compressed in a tablet press. The granulation preferably takes place in a fluidized bed granulator under suitable conditions.
- the active ingredient is admixed to the other pharmaceutical excipients in the form of a trituration with a pharmaceutical excipient (especially a filler).
- a pharmaceutical excipient especially a filler
- Such a trituration can normally be obtained by grinding the active ingredient with a pharmaceutical excipient (especially a filler).
- the invention therefore also relates to a process for producing a dosage form in tablet or pellet form for oral administration of a PDE 4 inhibitor comprising the steps:
- the dosage form of the invention is particularly preferably produced by granulation of a mixture of
- the PDE 4 inhibitor whose solubility is slight is in this case particularly preferably roflumilast, the salts thereof, the N-oxide of the pyridine and salts thereof.
- the dosage form of the invention is particularly preferably produced by granulation of a mixture of
- the PDE 4 inhibitor whose solubility is slight is in this case particularly preferably roflumilast, the salts thereof, the N-oxide of the pyridine and salts thereof.
- the dosage form of the invention is produced by granulation of a mixture of pharmaceutical excipients with a suspension of the active ingredient in an aqueous PVP solution, drying of the granules and, if desired, admixture of further pharmaceutical excipients.
- the preparations obtained in this way can then, after mixing with a release agent, be compressed in a tablet press.
- the granulation preferably takes place in a fluidized bed granulator under suitable conditions.
- the invention therefore also relates to a process for producing a dosage form in tablet or pellet form for oral administration of a PDE 4 inhibitor comprising the steps:
- the dosage form of the invention is particularly preferably produced by granulation of a mixture of corn starch and lactose monohydrate with a suspension of the PDE 4 inhibitor whose solubility is slight in an aqueous solution of PVP, drying of the granules, mixing of the granules with a release agent and compression in a tablet press. It has surprisingly been found that dosage forms of the invention produced employing physical mixtures or triturations of the PDE 4 inhibitor whose solubility is slight with a filler (e.g.
- Figure 1 shows the time course of the average serum concentration of roflumilast after oral administration of 0.5 mg (2 tablets each containing 0.25 mg) of roflumilast from dosage forms of the invention compared with a dosage form containing no PVP.
- (1) is mixed with part of (3), and a trituration is produced in a planetary mill.
- the trituration is put together with (2) and the remaining amount of (3) in the product container of a fluidized bed granulation system, and a 5% granulation solution of (4) in purified water is sprayed on and dried under suitable conditions.
- (5) is added to the granules, and the mixture obtained after mixing is compressed in a tablet press to tablets having an average weight of 65.1 mg.
- (1) is mixed with part of (3), and a trituration is produced in a planetary mill.
- the trituration is put together with (2), (5) and the remaining amount of (3) in the product container of a fluidized bed granulation system, and a 5% granulation solution of (4) in purified water is sprayed on and dried under suitable conditions.
- (6) is added to the granules, and the mixture obtained after mixing is compressed in a tablet press to tablets having an average weight of 59.5 mg.
- (1) is mixed with part of (3), and a trituration is produced in a planetary mill.
- the trituration is put together with (2), (5) and the remaining amount of (3) in the product container of a fluidized bed granulation system, and a 5% granulation solution of (4) in purified water is sprayed on and dried under suitable conditions.
- (6) is added to the granules, and the mixture obtained after mixing is compressed in a tablet press to tablets having an average weight of 61.75 mg.
- Magnesium stearate (vegetable) 45.500 g Total 4557.000 g
- (1) is mixed with 70 g of (3), and a trituration is produced in a planetary mill.
- the trituration is put together with (2) and the remaining amount of (3) in the product container of a fluidized bed granulation system, and a 5% granulation solution of (4) in purified water is sprayed on.
- Spray pressure 3 bar; product temperature: 28-33°C; air flow rate in the first third of the spraying process: 100 m 3 /h; air flow rate subsequently during the spraying process: 150 m 3 /h; inlet air temperature: 40-70°C; spraying rate: 30-40 g/min).
- spraying is complete, drying is carried out until the product temperature reaches 34°C.
- the granules are passed through a stainless steel sieve with a mesh width of 0.8 mm, and the relative surface moisture is measured and adjusted to a value in the range 20-50%. (5) is added to the granules, and the mixture obtained after mixing is compressed in a tablet press to tablets having an average weight of 65.1 mg.
- Magnesium stearate (vegetable) 45.500 g Total 4585.000 g
- the granules are passed through a stainless steel sieve with a mesh width of 0.8 mm, and the relative surface moisture is measured and adjusted to a value in the range 20-50%. (5) is added to the granules, and the mixture obtained after mixing is compressed in a tablet press to tablets having an average weight of 65.5 mg.
- Magnesium stearate (veget able) 45.500 g
- (1) is homogeneously suspended in a granulation solution of (4) in purified water.
- (2) and (3) are put into the product container of a suitable fluidized bed granulation system and granulated with the granulation suspension described above, and then dried.
- (5) is added to the granules, and the mixture obtained after mixing is compressed in a tablet press to tablets having an average weight of 65.25 mg.
- a dispersion is produced from (4) and WO
- the formulation is produced according to a process disclosed above. Physical investigations and comparative tests with dosage forms in which no PVP was used as binder
- Disintegration time the disintegration time was determined using a disintegration tester by the method described in the European Pharmacopoeia. Result: 7.08 minutes.
- a dispersion is produced from (4) and water, and (1) is homogeneously suspended therein. (2) and (3) are granulated in a suitable fluidized bed granulation system with the dispersion under suitable conditions. (5) is added to the dry granules, and a homogeneous mixture is produced. (5) is added to this mixture, and the mixture obtained after mixing is compressed in a tablet press to tablets having an average weight of 96.438 mg. Comparative study
- treatment A Tablet corresponding to example D, referred to as "treatment A" hereinafter.
- treatment B Tablet corresponding to example K, referred to as "treatment B" hereinafter.
- treatment C Tablet corresponding to example O, referred to as "treatment C" hereinafter.
- the dosage forms of the invention can be employed for the treatment and prevention of all diseases regarded as treatable or preventable through the use of PDE 4 inhibitors.
- Selective cyclic nucleotide phosphodiesterase (PDE) inhibitors are suitable on the one hand as bronchial therapeutic agents (for the treatment of airway obstructions owing to their dilating effect but also owing to their effect increasing the respiratory rate and respiratory drive) and for eliminating erectile dysfunction owing to the vasodilating effect, but on the other hand especially for the treatment of disorders, especially of an inflammatory nature, e.g.
- mediators such as histamine, PAF (platelet-activating factor), arachidonic acid derivatives such as leukotrienes and prostaglandins, cytokines, interleukins, chemokines, alpha-, beta- and gamma- interferon, tumor necrosis factor (TNF) or oxygen free radicals and proteases.
- mediators such as histamine, PAF (platelet-activating factor), arachidonic acid derivatives such as leukotrienes and prostaglandins, cytokines, interleukins, chemokines, alpha-, beta- and gamma- interferon, tumor necrosis factor (TNF) or oxygen free radicals and proteases.
- mediators such as histamine, PAF (platelet-activating factor), arachidonic acid derivatives such as leukotrienes and prostaglandins, cytokines, interleukins, chemokines, alpha-, beta- and gamma- interferon
- the pharmaceutical preparations of the invention can therefore be used in human and veterinary medicine for example for the treatment and prophylaxis of the following diseases: acute and chronic (especially inflammatory and allergen-induced) airway disorders of various etiologies (bronchitis, allergic bronchitis, bronchial asthma, COPD); dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders; disorders based on excessive release of TNF an le
- disorders of the arthritic type rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic states
- disorders of the immune system AIDS, multiple sclerosis
- types of shock septic shock, endotoxin shock, gram-negative sepsis, toxic shock syndrome and ARDS (adult respiratory distress syndrome)] and generalized inflammations in the gastrointestinal region (Crohn's disease and ulcerative colitis
- cardiac disorders which can be treated by PDE inhibitors such as, for example, heart failure, or disorders which can be treated owing to the tissue-relaxant effect of PDE inhibitors
- the invention further relates to a method for the treatment of mammals, including humans, suffering from one of the abovementioned diseases.
- the method is characterized by administration of a therapeutically effective and pharmacologically suitable amount of a PDE 4 inhibitor to the mammalian patient, the PDE 4 inhibitor being present in a dosage form of the invention.
- the dosage forms of the invention comprise the PDE 4 inhibitor in the dose customary for the treatment of the particular disease.
- the dosage of the active ingredient is of the order of magnitude customary for PDE inhibitors, it being possible to administer the daily dose in one or more dosage units.
- the normal dose on systemic therapy is between 0.001 mg and 3 mg per kilogram and day.
- Dosage forms preferred according to the invention contain from 0.01 mg to 5 mg of roflumilast, preferably from 0.05 mg to 2.5 mg, particularly preferably 0.1 mg to 0.5 mg of roflumilast per dosage unit.
- Examples of pharmaceutical preparations of the invention contain 0.1 mg, 0.125 mg, 0.25 mg and 0.5 mg of roflumilast per dosage unit.
- one or more than one dosage unit of the invention is administered once a day. If desired, it is also possible for one or more dosage units of the invention to be administered more than once a day.
Abstract
Description
Claims
Priority Applications (37)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200401019A EA008219B1 (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
CN038042304A CN1635909B (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
DK03704652.1T DK1478399T3 (en) | 2002-02-20 | 2003-02-19 | ORAL DOSAGE FORM CONTAINING A PDE-4 INHIBITOR AS AN ACTIVE INGREDIENT AND POLYVINYLPYRROLIDONE AS EXCIPIENT |
BR0307739-0A BR0307739A (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a powder inhibitor 4 as an active ingredient and polyvinylpyrrolidone as an excipient |
CA2475923A CA2475923C (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
SI200332160T SI1478399T1 (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
MEP-2008-855A ME00566B (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
UA20040907576A UA84266C2 (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyroolidon as excipient, processes for the preparation and use thereof |
AU2003206924A AU2003206924B2 (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
JP2003569234A JP4163120B2 (en) | 2002-02-20 | 2003-02-19 | Oral dosage form with PDE4 inhibitor as active ingredient and polyvinylpyrrolidone as additive |
MXPA04005759A MXPA04005759A (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient. |
YU73604A RS52548B (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
ES03704652T ES2384378T3 (en) | 2002-02-20 | 2003-02-19 | Oral pharmaceutical form containing a PDE 4 inhibitor as active ingredient and polyvinylpyrrolidone as an excipient |
PL370595A PL226401B1 (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
AT03704652T ATE550038T1 (en) | 2002-02-20 | 2003-02-19 | ORAL DOSAGE FORM CONTAINING A PDE-4 INHIBITOR AS AN ACTIVE INGREDIENT AND POLYVINYLPYRROLIDONE AS AN EXCIPIENT |
KR1020107019428A KR101386843B1 (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
EP03704652A EP1478399B1 (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
KR1020047012904A KR101253033B1 (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
IL16284303A IL162843A0 (en) | 2002-02-20 | 2003-02-19 | Dosage form for oral administration of a pde4 inhibitor |
US10/505,138 US7951397B2 (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
NZ535197A NZ535197A (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
TNP2004000124A TNSN04124A1 (en) | 2002-02-20 | 2004-07-02 | Oral dosage from containning a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
IL162843A IL162843A (en) | 2002-02-20 | 2004-07-04 | Dosage form for oral administration of a pde4 inhibitor |
IS7410A IS7410A (en) | 2002-02-20 | 2004-08-18 | Oral dosage form containing PDE 4 active ingredient and polyvinylpyrrolidone as an excipient |
NO20043904A NO332844B1 (en) | 2002-02-20 | 2004-11-22 | Oral dosage form containing a PDE4 inhibitor as active ingredient and polyvinylpyrrolidone as the excipient, its use and method for preparing the same. |
HK05109914.9A HK1077752A1 (en) | 2002-02-20 | 2005-11-07 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
US11/501,836 US20060269600A1 (en) | 2002-02-20 | 2006-08-10 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
US12/876,996 US20110060016A1 (en) | 2002-02-20 | 2010-09-07 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
US13/008,842 US8431154B2 (en) | 2002-02-20 | 2011-01-18 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
US13/739,457 US20130131123A1 (en) | 2002-02-20 | 2013-01-11 | Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient |
US13/874,065 US9468598B2 (en) | 2002-02-20 | 2013-04-30 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
US14/038,666 US20140031396A1 (en) | 2002-02-20 | 2013-09-26 | Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient |
US14/038,678 US20140031397A1 (en) | 2002-02-20 | 2013-09-26 | Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient |
IL237196A IL237196A0 (en) | 2002-02-20 | 2015-02-12 | Dosage form for oral administration of a pde4 inhibitor whose solubility is slight |
US14/731,964 US20150290178A1 (en) | 2002-02-20 | 2015-06-05 | Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient |
US14/735,015 US20150290180A1 (en) | 2002-02-20 | 2015-06-09 | Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient |
US14/735,004 US20150290179A1 (en) | 2002-02-20 | 2015-06-09 | Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10207160.8 | 2002-02-20 | ||
EP02003811 | 2002-02-20 | ||
EP02003811.3 | 2002-02-20 | ||
DE2002107160 DE10207160A1 (en) | 2002-02-20 | 2002-02-20 | Dosage form useful for treating diseases e.g. psoriasis, allergic contact eczema, atopic eczema, sunburn and pruritis comprises phosphodiesterase inhibitor and polyvinylpyrrolidone |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/505,138 A-371-Of-International US7951397B2 (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
US11/501,836 Continuation US20060269600A1 (en) | 2002-02-20 | 2006-08-10 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
US13/008,842 Continuation US8431154B2 (en) | 2002-02-20 | 2011-01-18 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003070279A1 true WO2003070279A1 (en) | 2003-08-28 |
Family
ID=27758398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/001650 WO2003070279A1 (en) | 2002-02-20 | 2003-02-19 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
Country Status (34)
Country | Link |
---|---|
US (11) | US7951397B2 (en) |
EP (2) | EP2258394B1 (en) |
JP (1) | JP4163120B2 (en) |
KR (2) | KR101253033B1 (en) |
CN (2) | CN102764242B (en) |
AR (1) | AR038527A1 (en) |
AT (1) | ATE550038T1 (en) |
AU (1) | AU2003206924B2 (en) |
BR (1) | BR0307739A (en) |
CA (1) | CA2475923C (en) |
CY (2) | CY1112811T1 (en) |
DK (2) | DK2258394T3 (en) |
EA (1) | EA008219B1 (en) |
EC (1) | ECSP045238A (en) |
ES (2) | ES2384378T3 (en) |
GE (1) | GEP20074079B (en) |
HK (1) | HK1077752A1 (en) |
IL (3) | IL162843A0 (en) |
IS (1) | IS7410A (en) |
MA (1) | MA27100A1 (en) |
ME (1) | ME00566B (en) |
MX (1) | MXPA04005759A (en) |
MY (1) | MY140561A (en) |
NO (1) | NO332844B1 (en) |
NZ (1) | NZ535197A (en) |
PE (1) | PE20030823A1 (en) |
PL (1) | PL226401B1 (en) |
PT (2) | PT2258394E (en) |
RS (1) | RS52548B (en) |
SI (2) | SI1478399T1 (en) |
TN (1) | TNSN04124A1 (en) |
TW (1) | TWI363636B (en) |
UA (1) | UA84266C2 (en) |
WO (1) | WO2003070279A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004080967A1 (en) | 2003-03-10 | 2004-09-23 | Altana Pharma Ag | Novel process for the preparation of roflumilast |
WO2004103407A2 (en) | 2003-05-22 | 2004-12-02 | Altana Pharma Ag | Composition comprising a pde4 inhibitor and a pde5 inhibitor |
WO2005041855A2 (en) * | 2003-10-29 | 2005-05-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation containing an ltb4 antagonist, method for the production thereof, and use thereof |
ES2245891A1 (en) * | 2004-07-09 | 2006-01-16 | Clinmet S.L. | Formation of a universal excipient for oral pharmaceuticals administration consists of incorporation of aqueous solution in the active principal of the pharmaceutical |
WO2006097456A1 (en) * | 2005-03-16 | 2006-09-21 | Nycomed Gmbh | Taste masked dosage form containing roflumilast |
WO2006111495A1 (en) * | 2005-04-19 | 2006-10-26 | Nycomed Gmbh | Roflumilast for the treatment of pulmonary hypertension |
WO2008093221A2 (en) * | 2007-02-01 | 2008-08-07 | Glenmark Pharmaceuticals, S.A. | Pharmaceutical compositions containing pde4 inhibitor for the treatment of inflammatory and allergic disorders |
EP2186521A1 (en) * | 2008-11-14 | 2010-05-19 | Mergemeier Steffen | Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound |
US7951397B2 (en) | 2002-02-20 | 2011-05-31 | Nycomed Gmbh | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
JP2011126912A (en) * | 2003-05-08 | 2011-06-30 | Nycomed Gmbh | Dosage form containing pantoprazole as active ingredient |
EP2359826A1 (en) | 2006-07-05 | 2011-08-24 | Nycomed GmbH | Combination of HMG-COA reductase inhibitors, such as roflumilast, roflumilast-N-oxide with a phosphodiesterase 4 inhibitor, rosuvastatin, for the treatment of inflammatory pulmonary diseases |
CN103330689A (en) * | 2013-03-31 | 2013-10-02 | 北京万全德众医药生物技术有限公司 | Orally disintegrating tablet comprising roflumilast |
US9149532B2 (en) * | 2007-03-29 | 2015-10-06 | Daiichi Sanykyo Company, Limited | Pharmaceutical composition |
US9205044B2 (en) * | 2004-09-22 | 2015-12-08 | Takeda Gmbh | Aqueous pharmaceutical preparation comprising roflumilast |
WO2016016824A1 (en) | 2014-07-29 | 2016-02-04 | Fundacio Hospital Universitari Vall D' Hebron-Institut De Recerca | Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis |
US9402907B2 (en) | 2011-08-10 | 2016-08-02 | Daiichi Sankyo Company, Limited | Pharmaceutical composition containing diamine derivative |
WO2016120746A1 (en) * | 2015-01-29 | 2016-08-04 | Micro Labs Limited | A pharmaceutical composition comprising roflumilast |
US9504663B2 (en) | 2011-02-07 | 2016-11-29 | Scipharm Sarl | Composition for the treatment of cystic fibrosis |
US9918975B2 (en) | 2010-03-19 | 2018-03-20 | Daiichi Sankyo Company, Limited | Method for improving dissolution of anticoagulant agent |
RU2659206C2 (en) * | 2016-04-14 | 2018-06-28 | Общество с ограниченной ответственностью "Технофарм" | Composition and method for industrial production of digoxin trituration (options) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2140861A1 (en) * | 2008-06-30 | 2010-01-06 | Abbott GmbH & Co. KG | Pharmaceutical dosage form comprising polymeric carrier composition |
JP5568139B2 (en) | 2010-10-22 | 2014-08-06 | デウー シップビルディング アンド マリン エンジニアリング カンパニー リミテッド | LNG storage container |
CN102274222B (en) * | 2011-08-18 | 2013-04-10 | 天津市汉康医药生物技术有限公司 | High-bioavailability roflumilast medicinal composition and preparation method thereof |
WO2013030789A1 (en) | 2011-08-30 | 2013-03-07 | Ranbaxy Laboratories Limited | Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor |
SI2797581T1 (en) * | 2011-12-27 | 2020-08-31 | Amgen (Europe) GmbH | Formulations of (+)-2-(1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl)-4-acetyl aminoisoindoline-1,3-dione |
CN103446070B (en) * | 2012-05-31 | 2016-06-22 | 天津康鸿医药科技发展有限公司 | A kind of roflumilast solid immediate release preparation and preparation method thereof |
WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
CN103565806A (en) * | 2012-07-31 | 2014-02-12 | 江苏柯菲平医药有限公司 | Roflumilast oral preparation and preparation method thereof |
NZ706356A (en) * | 2012-09-06 | 2018-02-23 | Mcpharma Biotech Inc | Treatment of diarrhea and post-weaning diarrhea with resistant potato starch |
CN102871976A (en) * | 2012-09-29 | 2013-01-16 | 华润赛科药业有限责任公司 | Tablet containing roflumilast as active ingredients and preparation method of tablet |
CN102949370B (en) * | 2012-11-27 | 2018-05-04 | 贵州信邦制药股份有限公司 | A kind of Roflumilast tablet and preparation method thereof and detection method |
CN103127011B (en) * | 2012-12-27 | 2014-11-26 | 深圳万乐药业有限公司 | Roflumilast tablet and preparation method thereof |
WO2015022418A1 (en) | 2013-08-16 | 2015-02-19 | Takeda Gmbh | Treatment of cognitive impairment with pde4 inhibitor |
EP3043798A4 (en) * | 2013-09-13 | 2017-04-12 | Hetero Research Foundation | Pharmaceutical compositions of roflumilast and process for preparation thereof |
WO2015132708A1 (en) * | 2014-03-07 | 2015-09-11 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of roflumilast |
US9969688B2 (en) | 2014-10-24 | 2018-05-15 | Hisamitsu Pharmaceutical Co., Inc. | Roflumilast prodrugs |
CN106176639A (en) * | 2015-04-30 | 2016-12-07 | 四川科伦药物研究院有限公司 | A kind of method preparing Roflumilast tablet |
CN106139161A (en) * | 2016-08-12 | 2016-11-23 | 合肥久诺医药科技有限公司 | A kind of roflumilast clathrate and solid preparation thereof |
JP7019978B2 (en) * | 2017-06-30 | 2022-02-16 | 富士電機株式会社 | Equipment management system, equipment management method and program |
US11534493B2 (en) | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
CN116726362A (en) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | Methods and devices for treating diseases with biologic therapeutic agents |
CN115666704A (en) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | Ingestible device for delivery of therapeutic agents to the gastrointestinal tract |
CN111643470A (en) * | 2020-04-30 | 2020-09-11 | 山东希尔康泰药业有限公司 | Preparation process of roflumilast film-coated tablets |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
US11504332B2 (en) * | 2021-03-23 | 2022-11-22 | Vk Research Associates Inc. | Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof |
US20240108609A1 (en) | 2022-09-15 | 2024-04-04 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340827A (en) * | 1992-06-15 | 1994-08-23 | Celltech, Limited | Phenylcarboxamide compounds which have useful pharmaceutical activity |
US6218400B1 (en) * | 1995-07-14 | 2001-04-17 | Icos Corporation | Treatment method using a cGMP-Specific PDE inhibitor |
EP1120120A1 (en) * | 1998-10-05 | 2001-08-01 | Eisai Co., Ltd. | Tablets immediately disintegrating in the oral cavity |
US6348602B1 (en) * | 1999-12-23 | 2002-02-19 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
WO2002045693A1 (en) * | 2000-12-07 | 2002-06-13 | Altana Pharma Ag | Pharmaceutical preparation comprising an active dispersed on a matrix |
Family Cites Families (213)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3065142A (en) | 1958-07-30 | 1962-11-20 | Armour Pharma | Gastric resistant medicinal preparation |
US4006227A (en) | 1973-11-15 | 1977-02-01 | Gallegos Alfred J | Compositions and methods for fertility control |
US4024240A (en) * | 1975-07-18 | 1977-05-17 | Eli Lilly And Company | Antibiotic A-32390 compositions |
US4343804A (en) | 1979-03-26 | 1982-08-10 | A. H. Robins Company, Inc. | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds |
ZA81219B (en) | 1980-01-23 | 1982-01-27 | Schering Corp | Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them |
NZ196700A (en) * | 1980-04-18 | 1983-04-12 | Smith & Nephew Ass | Anti-inflammatory compositions containing 5-benzoyl-1-methylpyrrole-2-acetic acid derivatives |
DE3269604D1 (en) * | 1981-06-26 | 1986-04-10 | Schering Corp | Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them |
US4464372A (en) | 1982-08-16 | 1984-08-07 | Schering Corporation | Imidazo[1,2-b]pyridazines |
GB8305245D0 (en) | 1983-02-25 | 1983-03-30 | Fujisawa Pharmaceutical Co | Imidazo-heterocyclic compounds |
DE3308239A1 (en) | 1983-03-09 | 1984-09-13 | Basf Ag, 6700 Ludwigshafen | N-ACYL-ANTHRANILE ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR CONTROLLING UNWANTED PLANT GROWTH |
GB8307865D0 (en) * | 1983-03-22 | 1983-04-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
DK159431C (en) | 1984-05-10 | 1991-03-18 | Byk Gulden Lomberg Chem Fab | 6-PHENYL-3 (2H) -PYRIDAZINONES, METHOD OF PREPARING THEREOF, PHARMACEUTICALS CONTAINING THESE AND USING THE COMPOUNDS FOR THE PREPARATION OF MEDICINAL PRODUCTS |
GB8415540D0 (en) * | 1984-06-18 | 1984-07-25 | Fujisawa Pharmaceutical Co | Imidazoisoquinoline compounds |
JPS61205208A (en) | 1985-03-08 | 1986-09-11 | Yamanouchi Pharmaceut Co Ltd | Rapidly solubilizing preparation for hard-soluble medicines |
US4725601A (en) * | 1985-06-04 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers |
JPS61205208U (en) | 1985-06-12 | 1986-12-24 | ||
JPS625966A (en) | 1985-07-03 | 1987-01-12 | Nippon Shinyaku Co Ltd | Benzimidazole derivative |
EP0228006A1 (en) | 1985-12-16 | 1987-07-08 | Fujisawa Pharmaceutical Co., Ltd. | Imidazopyridine compounds and processes for preparation thereof |
US4753945A (en) | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
JPH0249720Y2 (en) | 1986-05-08 | 1990-12-27 | ||
US5286494A (en) | 1986-07-02 | 1994-02-15 | Schering Aktiengesellschaft | Medicinal agents with sustained action |
GB8621425D0 (en) | 1986-09-05 | 1986-10-15 | Smith Kline French Lab | Compounds |
US4833149A (en) | 1986-09-22 | 1989-05-23 | Ortho Pharmaceutical Corporation | 2- or 3-aryl substituted imidazo[1,2-a]pyridines |
US4791117A (en) | 1986-09-22 | 1988-12-13 | Ortho Pharmaceutical Corporation | 2- or 3-aryl substituted imidazo[1,2-a]pyridines and their use as calcium channel blockers |
EP0266890A1 (en) | 1986-10-07 | 1988-05-11 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives, their production, and pharmaceutical compositions containing them |
EP0264883A3 (en) | 1986-10-21 | 1990-04-04 | Banyu Pharmaceutical Co., Ltd. | Substituted pyridine derivatives |
US4831041A (en) | 1986-11-26 | 1989-05-16 | Fujisawa Pharmaceutical Co., Ltd. | Imidazopyridine compounds and processes for preparation thereof |
US5112834A (en) * | 1987-07-16 | 1992-05-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Imidazole protectorant for the stomach and intestine |
GB8717644D0 (en) | 1987-07-24 | 1987-09-03 | Smithkline Beckman Intercredit | Compounds |
GB8722488D0 (en) * | 1987-09-24 | 1987-10-28 | Fujisawa Pharmaceutical Co | Imidazopyridine compound |
GB8804444D0 (en) * | 1988-02-25 | 1988-03-23 | Smithkline Beckman Intercredit | Compounds |
US4900775A (en) | 1988-02-29 | 1990-02-13 | Gaf Chemicals Corporation | Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone |
US5011843A (en) | 1988-05-31 | 1991-04-30 | Iolab Corporation | Treatment of glaucoma using phosphodiesterase inhibitors |
WO1990005136A1 (en) | 1988-11-07 | 1990-05-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | New imidazopyridines |
KR900014376A (en) | 1989-03-13 | 1990-10-23 | 후지사와 토모키치로 | Imidazo pyridine compound and preparation method thereof |
CA2011086A1 (en) | 1989-03-17 | 1990-09-17 | Karl-Heinz Geiss | 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom |
GB8908229D0 (en) | 1989-04-12 | 1989-05-24 | Smithkline Beckman Intercredit | Compounds |
WO1990012789A1 (en) | 1989-04-17 | 1990-11-01 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel arylpyridazines, their manufacture, use and medicaments containing them |
DE3917232A1 (en) | 1989-05-26 | 1990-11-29 | Basf Ag | New N-aryl:methyl 4-amino-quinoline derivs - useful as gastrointestinal medicaments |
DE3917233A1 (en) | 1989-05-26 | 1990-11-29 | Basf Ag | 8-SUBSTITUTED 4- (HETEROCYCLYLMETHYLAMINO) -INCHINOLINES, THEIR USE AND DRUGS DERIVED THEREFROM |
DE3943385A1 (en) | 1989-12-27 | 1991-07-04 | Schering Ag | AGENT FOR TRANSDERMAL APPLICATION CONTAINING ROLIPRAM |
FR2657257B1 (en) | 1990-01-19 | 1994-09-02 | Rhone Poulenc Sante | PROCESS FOR THE PREPARATION OF DRUGS IN THE FORM OF PEARLS. |
AU634880B2 (en) | 1990-03-28 | 1993-03-04 | Otsuka Pharmaceutical Co., Ltd. | Quinoline derivative, antiulcer drug containing the same, and production of said derivative |
JP2816227B2 (en) | 1990-03-30 | 1998-10-27 | 日清製粉株式会社 | Anti-ulcer drug |
JP2851117B2 (en) | 1990-03-30 | 1999-01-27 | 日清製粉株式会社 | Indole derivatives and anti-ulcer drugs containing them as active ingredients |
PT97467A (en) | 1990-04-27 | 1992-01-31 | Byk Gulden Lomberg Chem Fab | METHOD FOR PREPARING NEW PYRIDAZINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
US5041442A (en) | 1990-07-31 | 1991-08-20 | Syntex (U.S.A.) Inc. | Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion |
AU8712191A (en) | 1990-10-15 | 1992-05-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | New diazines |
DE59109027D1 (en) | 1990-10-16 | 1998-08-13 | Byk Gulden Lomberg Chem Fab | Arylpyridazinone |
IE71647B1 (en) | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
US5935978A (en) | 1991-01-28 | 1999-08-10 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
US5698711A (en) * | 1991-01-28 | 1997-12-16 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
WO1992012969A1 (en) | 1991-01-29 | 1992-08-06 | Smithkline Beecham Intercredit B.V. | Salts of a 4-amino-3-acyl quinoline derivative and their use as inhibitors of gastric acid secretion |
SE9100920D0 (en) * | 1991-03-27 | 1991-03-27 | Astra Ab | NEW ACTIVE COMPOUNDS |
EP0581805A1 (en) | 1991-04-26 | 1994-02-09 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel pyridazines |
DK0587744T3 (en) * | 1991-05-28 | 2003-10-20 | Mcneil Ppc Inc | Chewable composition for release of a drug |
JP3108483B2 (en) * | 1991-09-30 | 2000-11-13 | 日清製粉株式会社 | Indole derivatives and anti-ulcer drugs containing the same as active ingredients |
JP3038064B2 (en) * | 1991-10-07 | 2000-05-08 | 日清製粉株式会社 | Indole derivatives and anti-ulcer drugs containing the same as active ingredients |
DE59209687D1 (en) | 1991-10-25 | 1999-06-02 | Byk Gulden Lomberg Chem Fab | PYRROLO-PYRIDAZINE WITH STOMACH AND COLON PROTECTIVE EFFECTS |
US5262171A (en) * | 1991-11-25 | 1993-11-16 | Isp Investments Inc. | Pharmaceutical tablet with PVP having enhanced drug dissolution rate |
GB9126438D0 (en) | 1991-12-12 | 1992-02-12 | Smithkline Beecham Intercredit | New quinoline derivatives |
DK0617612T3 (en) | 1991-12-18 | 1998-04-14 | Warner Lambert Co | Process for preparing a solid dispersion |
GB9200607D0 (en) | 1992-01-13 | 1992-03-11 | Ethical Pharma Ltd | Pharmaceutical compositions containing nifedipine and process for the preparation thereof |
GB9201692D0 (en) | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
GB9201694D0 (en) | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
GB9201693D0 (en) * | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
WO1993015044A1 (en) | 1992-01-29 | 1993-08-05 | Smithkline Beecham Corporation | N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as tnf and pde iv inhibitors |
WO1993015045A1 (en) | 1992-01-29 | 1993-08-05 | Smithkline Beecham Corporation | N-(3-phenylpropyl)oxamic acid, oxamate, and oxamide derivatives |
JP3523275B2 (en) | 1992-03-26 | 2004-04-26 | 東光薬品工業株式会社 | Patch |
JP3634861B2 (en) | 1992-06-15 | 2005-03-30 | セルテック リミテッド | Trisubstituted phenyl derivatives as selective phosphodiesterase IV inhibitors |
HUT72656A (en) | 1992-07-28 | 1996-05-28 | Rhone Poulenc Rorer Ltd | Inhibitors of c-amp phosphodiesterase and tnf, their preparation pharmaceuticals contg. them and their use |
US5891904A (en) | 1992-09-14 | 1999-04-06 | Wolf-Georg Forssmann | Use of inhibitors of phosphodiesterase IV |
JP3284622B2 (en) | 1992-10-23 | 2002-05-20 | ソニー株式会社 | Disk unit |
US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
KR0144833B1 (en) * | 1992-12-28 | 1998-07-15 | 김태훈 | Novel quinazoline derivatives and their preparation |
IL108520A (en) | 1993-02-15 | 1997-09-30 | Byk Gulden Lomberg Chem Fab | 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
PT695303E (en) * | 1993-04-22 | 2002-05-31 | Byk Gulden Lomberg Chem Fab | PYRIDINARY SALTS AND ITS EMPLOYMENT IN COMBATING BACTERIA HELICOBACTER |
DE4314963A1 (en) | 1993-05-06 | 1994-11-10 | Bayer Ag | Substituted pyridines and 2-oxo-1,2-dihydropyridines |
US5556863A (en) | 1993-06-11 | 1996-09-17 | Astra Aktiebolag | Compound for gastric acid secretion inhibition |
DE59410119D1 (en) | 1993-07-02 | 2002-06-20 | Byk Gulden Lomberg Chem Fab | FLUORALKOXY SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS |
EP0719561A4 (en) | 1993-08-10 | 1997-07-30 | Fujisawa Pharmaceutical Co | Percutaneously absorbable preparation |
JP3284686B2 (en) | 1993-08-30 | 2002-05-20 | 株式会社明電舎 | Brake torque control method of brake dynamometer system |
UA48122C2 (en) | 1993-10-11 | 2002-08-15 | Бік Гульден Ломберг Хеміше Фабрік Гмбх | IMIDAZO[1,2-a]PYRIDINE ALKOXYALKYL CARBAMATES, A PROCESS OF THEIR PREPARING AND A DRUG ON THEIR BASIS |
US5559110A (en) * | 1994-03-09 | 1996-09-24 | The Dupont Merck Pharmaceutical Company | Pharmaceutical formulations of cyclic urea type compounds |
SE9401197D0 (en) | 1994-04-11 | 1994-04-11 | Astra Ab | Active compounds |
ZA954599B (en) | 1994-06-07 | 1996-01-26 | Allergan Inc | Stable gel formulation for topical treatment of skin conditions |
PL180278B1 (en) | 1994-07-28 | 2001-01-31 | Byk Gulden Lomberg Chem Fab | Imidazopyridine azolydinones |
JP3031280B2 (en) | 1994-08-19 | 2000-04-10 | 東陶機器株式会社 | Toilet bowl cleaning equipment |
JPH0959152A (en) | 1995-08-18 | 1997-03-04 | Teisan Seiyaku Kk | Isosorbide dinitrate-containing plaster |
SE512835C2 (en) | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Dosage form containing a plurality of units all containing acid labile H + K + ATPase inhibitors |
US5677302A (en) | 1996-02-26 | 1997-10-14 | Apotex Inc. | Thiadiazole compounds useful as proton pump inhibitors |
US6114537A (en) | 1996-02-26 | 2000-09-05 | Apotex Inc. | Process for scavenging thiols |
FR2746800B1 (en) * | 1996-03-29 | 1998-06-05 | Jouveinal Inst Rech | DIAZEPINO-INDOLES PHOSPHODIESTERASE INHIBITORS 4 |
JP3031280U (en) | 1996-05-15 | 1996-11-22 | サン トップ コンピューター システムズ コーポレーション | Linear CCD bar code reader |
US5804588A (en) | 1996-05-20 | 1998-09-08 | Chiroscience Limited | Quinoline carboxanides and their therapeutic use |
US5972381A (en) | 1996-06-28 | 1999-10-26 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
US5762953A (en) | 1996-08-22 | 1998-06-09 | Theratech, Inc. | Transdermal propentofylline compositions for the treatment of Alzheimers disease |
TR199900481T2 (en) | 1996-09-04 | 1999-06-21 | Pfizer Inc. | Indazole derivatives; their use as phosphodiesterase type IV inhibitors. |
WO1998020858A1 (en) | 1996-11-12 | 1998-05-22 | Pharmacia & Upjohn Ab | COMPACT MEMBER COMPRISING A PLURALITY OF POROUS CELLULOSE MATRICES, (PCMs), METHOD OF MANUFACTURING AND USE THEREOF |
ATE336254T1 (en) | 1997-02-17 | 2006-09-15 | Altana Pharma Ag | COMPOSITIONS FOR THE TREATMENT OF IRDS OR ARDS CONTAINING 3-(CALCOPROPYLMETHOXY)-N-(3,5-DICHLORO-4-PYRIDI YL)-4-(DIFLUOROMETHOXY) BENZAMIDE AND LUNG SURFACTANT |
SE9700661D0 (en) * | 1997-02-25 | 1997-02-25 | Astra Ab | New compounds |
US6624181B1 (en) * | 1997-02-28 | 2003-09-23 | Altana Pharma Ag | Synergistic combination |
FR2762841B1 (en) | 1997-04-30 | 1999-07-02 | Jouveinal Inst Rech | DIAZEPINO-INDOLONES INHIBITING PHOSPHODIESTERASES IV |
EP0984969B1 (en) | 1997-05-28 | 2008-07-09 | Nycomed GmbH | Fused dihydropyrans |
IT1294748B1 (en) | 1997-09-17 | 1999-04-12 | Permatec Tech Ag | FORMULATION FOR A TRANSDERMAL DEVICE |
HUP0001555A3 (en) | 1997-10-30 | 2001-01-29 | Altana Pharma Ag | Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation |
ATE303809T1 (en) | 1997-12-08 | 2005-09-15 | Altana Pharma Ag | ORAL FORM OF ADMINISTRATION CONTAINING A PROTON PUMP INHIBITOR (E.G. PANTOPRAZOLE) |
SE9801526D0 (en) | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
KR100682154B1 (en) * | 1998-05-07 | 2007-02-12 | 코릭사 코포레이션 | Adjuvant composition and methods for its use |
CA2319495A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
ATE283033T1 (en) | 1998-07-24 | 2004-12-15 | Jago Res Ag | MEDICAL AEROSOL FORMULATIONS |
SE9802793D0 (en) | 1998-08-21 | 1998-08-21 | Astra Ab | New compounds |
SE9802794D0 (en) | 1998-08-21 | 1998-08-21 | Astra Ab | New compounds |
TR200100500T2 (en) * | 1998-08-26 | 2001-06-21 | Smithkline Beecham Corporation | Therapies for the treatment of pulmonary diseases |
US6436952B1 (en) | 1998-08-31 | 2002-08-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzonaphthyridine-N-oxides comprising a PDE3 and PDE4 inhibiting activity |
SI1115725T1 (en) * | 1998-09-23 | 2003-06-30 | Altana Pharma Ag | Tetrahydropyridoethers |
TR200200971T2 (en) | 1998-09-29 | 2002-06-21 | Fujisawa Pharmaceutical Co., Ltd. | New salts of the pyridopyrazine compound and their crystals. |
US6395746B1 (en) | 1998-09-30 | 2002-05-28 | Alcon Manufacturing, Ltd. | Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
US20020006418A1 (en) | 1998-10-13 | 2002-01-17 | John Kung | Composition to enhance permeation of topical skin agents |
EP1127059B1 (en) * | 1998-11-03 | 2008-02-20 | Nycomed GmbH | Imidazonaphthyridines |
DE19858331A1 (en) | 1998-12-17 | 2000-06-21 | Boehringer Ingelheim Pharma | Tricyclic nitrogen heterocycles as PDE IV inhibitors |
US6417190B1 (en) * | 1998-12-17 | 2002-07-09 | Boehringer Ingelheim Pharma Kg | Tricyclic nitrogen heterocycles as PDE IV inhibitors |
AR028986A1 (en) * | 1999-02-23 | 2003-06-04 | Smithkline Beecham Corp | USE OF A PDE4 INHIBITOR IN THE MANUFACTURE OF A CONTROLLED LIBERATION PREPARATION; FORMULATION OF CONTROLLED RELEASE FOR THE TREATMENT OF COPD, A PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION |
DZ3019A1 (en) | 1999-03-01 | 2005-05-20 | Smithkline Beecham Corp | Use of a pde4 inhibitor in the preparation of a drug against copd. |
US6270807B1 (en) | 1999-03-02 | 2001-08-07 | L. Perrigo Company | Taste-masked pharmaceutical composition |
PT1161239E (en) * | 1999-03-10 | 2005-02-28 | Altana Pharma Ag | 3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXY-N- (3,5-DICHLOROPYRID-4-YL) -BENZAMIDE FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
CN1126468C (en) | 1999-04-08 | 2003-11-05 | 王力田 | Black corn stalk beverage and preparing process thereof |
AU3966600A (en) | 1999-04-17 | 2000-11-02 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Haloalkoxy imidazonaphthyridines |
KR100328972B1 (en) | 1999-04-23 | 2002-03-20 | 서경배 | Method for Producing Cosmetic or Skincare-pharmaceutical Composition Containing Nutritional Supplement and the Cosmetic or Skincare-pharmaceutical Composition Produced by the Above-method |
PT1176960E (en) * | 1999-05-04 | 2005-02-28 | Altana Pharma Ag | COMBINATION SINERGICA UNDERSTANDING ROFLUMILAST AND A PDE-3 INHIBITOR |
DE19925710C2 (en) | 1999-06-07 | 2002-10-10 | Byk Gulden Lomberg Chem Fab | New preparation and dosage form containing an acid labile proton pump inhibitor |
SK285247B6 (en) | 1999-06-07 | 2006-09-07 | Altana Pharma Ag | Administration form for acid-labile active compounds, active compound unit, method for the production thereof and microsphere |
US7182958B1 (en) | 1999-08-03 | 2007-02-27 | Lilly Icos Llc. | β-carboline pharmaceutical compositions |
ES2260043T3 (en) * | 1999-08-21 | 2006-11-01 | Altana Pharma Ag | SYNERGIC COMBINATION OF ROFLUMILAST AND SALMETEROL. |
US6174878B1 (en) | 1999-08-31 | 2001-01-16 | Alcon Laboratories, Inc. | Topical use of kappa opioid agonists to treat otic pain |
US6375968B1 (en) | 1999-10-22 | 2002-04-23 | 3M Innovative Properties Company | Encapsulated active material immobilized in hydrogel microbeads |
WO2001035236A1 (en) | 1999-10-25 | 2001-05-17 | Sony Corporation | Method for managing content data |
KR20020050249A (en) | 1999-10-29 | 2002-06-26 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | Method for administering a phosphodiesterase 4 inhibitor |
US7076437B1 (en) | 1999-10-29 | 2006-07-11 | Victor Levy | Process for consumer-directed diagnostic and health care information |
US6985188B1 (en) | 1999-11-30 | 2006-01-10 | Thomson Licensing | Video decoding and channel acquisition system |
US6258833B1 (en) | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
NZ519726A (en) | 2000-01-31 | 2004-05-28 | Pfizer Prod Inc | Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes |
US6379682B1 (en) * | 2000-02-07 | 2002-04-30 | Color Access, Inc. | Clear water-in-oil emulsions |
US20030207845A1 (en) * | 2001-02-08 | 2003-11-06 | Keating Elizabeth T. | Method and compositions for treating an inflammatory disease |
EP1261331A4 (en) | 2000-02-16 | 2005-01-05 | Univ Nebraska Medical Ct | Method and compositions for treating fibrotic diseases |
PL363113A1 (en) * | 2000-03-27 | 2004-11-15 | Schott Glas | New cosmetic, personal care, cleaning agent, and nutritional supplement compositions comprising bioactive glass and methods of making and using the same |
GB0011802D0 (en) * | 2000-05-16 | 2000-07-05 | Smithkline Beecham | Method for enhancing cognitive function |
AU2001261962B2 (en) * | 2000-05-25 | 2005-04-21 | Merck Frosst Canada Ltd | Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor |
EP1161950A1 (en) * | 2000-06-09 | 2001-12-12 | Warner-Lambert Company | Use of diazepinoindoles for the treatment of chronic obstructive pulmonary disease |
AR029984A1 (en) | 2000-07-27 | 2003-07-23 | Smithkline Beecham Corp | METHOD FOR REDUCING ASSOCIATED EXCERBATIONS COPD AMBITO |
US20040005995A1 (en) * | 2001-07-26 | 2004-01-08 | Edelson Jeffrey D | Method for reducing exacerbations associated with copd |
EP1199074A1 (en) | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
US20020193393A1 (en) * | 2001-03-07 | 2002-12-19 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
CA2427814C (en) | 2000-11-07 | 2009-06-02 | Merck & Co., Inc. | A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders |
US20100310477A1 (en) * | 2000-11-28 | 2010-12-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg. | Pharmaceutical compositions based on anticholingerics and additional active ingredients |
CN100528232C (en) | 2000-12-07 | 2009-08-19 | 尼科梅德有限责任公司 | Pharmaceutical preparation in form of suspension comprising acid-labile active ingredient |
DE10061137B4 (en) | 2000-12-07 | 2016-10-06 | Takeda Gmbh | New pharmaceutical preparation |
KR20030072555A (en) | 2000-12-07 | 2003-09-15 | 알타나 파마 아게 | Rapidly disintegrating tablet comprising an acid-labile active ingredient |
KR20030059314A (en) | 2000-12-07 | 2003-07-07 | 알타나 파마 아게 | Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient |
MXPA03007283A (en) | 2001-02-15 | 2003-12-04 | Tanabe Seiyaku Co | Tablets quickly disintegrated in oral cavity. |
WO2002069939A2 (en) | 2001-03-05 | 2002-09-12 | Ortho-Mcneil Pharmaceutical, Inc. | Taste masked pharmaceutical compositions |
FR2821745B1 (en) | 2001-03-09 | 2004-07-02 | Ethypharm Lab Prod Ethiques | GRANULES AND GRANULES COATED WITH MASK TASTE |
US6702796B2 (en) | 2001-03-26 | 2004-03-09 | The Procter & Gamble Company | Absorbent interlabial device having an improved tab |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
ATE347361T1 (en) | 2001-05-25 | 2006-12-15 | Boehringer Ingelheim Pharma | COMBINATION OF A PDE4 INHIBITOR WITH TIOTROPIUM FOR THE TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES |
RU2299066C2 (en) | 2001-06-27 | 2007-05-20 | Пробиодруг Аг | Novel inhibitors of dipeptidyl peptidase iv and their using as anticancer agents |
US20030092706A1 (en) * | 2001-11-09 | 2003-05-15 | Johannes Barsig | Combination |
US6723348B2 (en) | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
PT1478358E (en) | 2002-02-11 | 2013-09-11 | Bayer Healthcare Llc | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
US6756392B2 (en) * | 2002-02-11 | 2004-06-29 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
AU2003232148A1 (en) | 2002-05-16 | 2003-12-02 | Pharmacia Corporation | A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases |
US20030215498A1 (en) | 2002-05-17 | 2003-11-20 | Harland Ronald S. | Rapidly disintegrating comressed tablets comprising biologically active compounds |
ATE485821T1 (en) | 2002-05-28 | 2010-11-15 | Nycomed Gmbh | OPHTHALMOLOGICAL PREPARATION CONTAINING ROFLUMILAST IN THE TREATMENT OF EYE DISEASES |
US20030235631A1 (en) | 2002-06-17 | 2003-12-25 | Pfizer Inc. | Combination treatment for depression and anxiety |
US20040058950A1 (en) * | 2002-07-09 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
US20040219142A1 (en) * | 2002-07-19 | 2004-11-04 | Abbott Laboratories S.A. | Treatment of skin and nail disorders using TNFalpha inhibitors |
US20030018071A1 (en) * | 2002-08-09 | 2003-01-23 | Rennard Stephen I. | Method and compositions for treating fibrotic diseases |
PL214701B1 (en) | 2002-08-10 | 2013-09-30 | Nycomed Gmbh | Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors |
WO2004019944A1 (en) | 2002-08-29 | 2004-03-11 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
WO2004022037A1 (en) | 2002-09-04 | 2004-03-18 | Ranbaxy Laboratories Limited | Taste masked dosage forms and processes for their preparation |
US6822114B1 (en) * | 2002-10-08 | 2004-11-23 | Albemarle Corporation | Process for production of fluoroalkoxy-substituted benzamides and their intermediates |
CA2506956C (en) * | 2002-11-27 | 2012-10-02 | Altana Pharma Ag | Synergistic combination comprising roflumilast and (r,r)-formoterol |
CA2506962C (en) * | 2002-11-27 | 2012-01-03 | Altana Pharma Ag | Synergistic combination comprising roflumilast and formoterol |
US20060159758A1 (en) * | 2002-12-11 | 2006-07-20 | Rajesh Gandhi | Coating composition for taste masking coating and methods for their application and use |
ATE444731T1 (en) | 2003-01-30 | 2009-10-15 | Ethypharm Sa | FLAVOR-MASKED COATED PARTICLES, METHOD OF PRODUCTION AND ORAL-DISPPERSIBLE TABLETS CONTAINING THE COATED PARTICLES |
PT1606261E (en) | 2003-03-10 | 2010-01-11 | Nycomed Gmbh | Novel process for the preparation of roflumilast |
DE602004011494T2 (en) * | 2003-03-28 | 2009-01-22 | Nycomed Gmbh | SYNERGISTIC COMBINATION CONTAINS ROFLUMILAST AND AN ANTICHOLINERGIC AGENT SELECTED FROM TIOTROPIUM SALTS FOR THE TREATMENT OF RESPIRATORY DISEASES |
EA012279B1 (en) | 2003-05-22 | 2009-08-28 | Никомед Гмбх | Composition comprising a pde4 inhibitor and a pde5 inhibitor |
US20050026883A1 (en) | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
EP1656117A1 (en) * | 2003-08-11 | 2006-05-17 | Merck Frosst Canada Ltd. | Flavored taste-masked pharmaceutical formulation made using a one-step coating process |
WO2005020961A1 (en) | 2003-08-28 | 2005-03-10 | Sandoz Ag | Pharmaceutical composition comprising anticonvulsant with taste mask coating |
WO2005026095A1 (en) | 2003-09-12 | 2005-03-24 | Ranbaxy Laboratories Limited | Process for the preparation of roflumilast |
AU2004279438A1 (en) | 2003-10-09 | 2005-04-21 | Inverseon, Inc. | Methods for treating diseases and conditions with inverse agonists |
WO2005041864A2 (en) | 2003-10-21 | 2005-05-12 | Pharmacia Corporation | Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method |
US20070111995A1 (en) | 2003-12-19 | 2007-05-17 | Allen David G | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors |
JP2007536350A (en) * | 2004-05-10 | 2007-12-13 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Use of roflumilast for the prevention or treatment of emphysema |
DE102004046235A1 (en) | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | drug preparation |
US7562356B2 (en) * | 2004-09-22 | 2009-07-14 | Hewlett-Packard Development Company, L.P. | Automatically resolving patch dependencies for a path bundle |
US7884059B2 (en) * | 2004-10-20 | 2011-02-08 | Afton Chemical Corporation | Oil-soluble molybdenum derivatives derived from hydroxyethyl-substituted Mannich bases |
US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
WO2006094640A2 (en) | 2005-03-04 | 2006-09-14 | F.Hoffmann-La Roche Ag | Roflumilast and integrin inhibitor combination and method of treatment |
EP2258350B1 (en) | 2005-03-16 | 2014-12-24 | Takeda GmbH | Taste masked dosage form containing roflumilast |
US20060293343A1 (en) | 2005-05-18 | 2006-12-28 | Asahi Kasei Pharma Corporation | Pyrimidine derivatives |
US20090291950A1 (en) | 2006-07-07 | 2009-11-26 | Kalypsys, Inc. | Bicyclic heteroaryl inhibitors of pde4 |
USD580547S1 (en) * | 2007-07-31 | 2008-11-11 | Nycomed Gmbh | Tablet |
JP5271070B2 (en) | 2008-12-24 | 2013-08-21 | エスアイアイ・プリンテック株式会社 | Head chip, liquid ejecting head, and liquid ejecting apparatus |
US20120052122A1 (en) | 2010-08-26 | 2012-03-01 | Nycomed Gmbh | Treatment Of Chronic Obstructive Pulmonary Disease With Phosphodiesterase-4 Inhibitor |
EP2704697B1 (en) | 2011-05-06 | 2018-09-12 | GlaxoSmithKline Consumer Healthcare (UK) IP Limited | Sustained release paracetamol formulations |
SI2834241T1 (en) | 2012-03-05 | 2021-06-30 | Gilead Calistoga Llc | Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one |
US8921307B2 (en) | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
-
2003
- 2003-02-13 MY MYPI20030495A patent/MY140561A/en unknown
- 2003-02-18 PE PE2003000169A patent/PE20030823A1/en not_active Application Discontinuation
- 2003-02-18 TW TW092103296A patent/TWI363636B/en not_active IP Right Cessation
- 2003-02-19 SI SI200332160T patent/SI1478399T1/en unknown
- 2003-02-19 CN CN201210231798.1A patent/CN102764242B/en not_active Expired - Lifetime
- 2003-02-19 KR KR1020047012904A patent/KR101253033B1/en active IP Right Review Request
- 2003-02-19 EP EP10173234.5A patent/EP2258394B1/en not_active Revoked
- 2003-02-19 EP EP03704652A patent/EP1478399B1/en not_active Revoked
- 2003-02-19 GE GEAP8411A patent/GEP20074079B/en unknown
- 2003-02-19 NZ NZ535197A patent/NZ535197A/en not_active IP Right Cessation
- 2003-02-19 SI SI200332288T patent/SI2258394T1/en unknown
- 2003-02-19 AT AT03704652T patent/ATE550038T1/en active
- 2003-02-19 RS YU73604A patent/RS52548B/en unknown
- 2003-02-19 DK DK10173234.5T patent/DK2258394T3/en active
- 2003-02-19 MX MXPA04005759A patent/MXPA04005759A/en active IP Right Grant
- 2003-02-19 WO PCT/EP2003/001650 patent/WO2003070279A1/en active Application Filing
- 2003-02-19 PT PT101732345T patent/PT2258394E/en unknown
- 2003-02-19 JP JP2003569234A patent/JP4163120B2/en not_active Expired - Fee Related
- 2003-02-19 ES ES03704652T patent/ES2384378T3/en not_active Expired - Lifetime
- 2003-02-19 BR BR0307739-0A patent/BR0307739A/en not_active Application Discontinuation
- 2003-02-19 CN CN038042304A patent/CN1635909B/en not_active Expired - Lifetime
- 2003-02-19 UA UA20040907576A patent/UA84266C2/en unknown
- 2003-02-19 PT PT03704652T patent/PT1478399E/en unknown
- 2003-02-19 IL IL16284303A patent/IL162843A0/en active IP Right Grant
- 2003-02-19 KR KR1020107019428A patent/KR101386843B1/en active IP Right Review Request
- 2003-02-19 DK DK03704652.1T patent/DK1478399T3/en active
- 2003-02-19 AU AU2003206924A patent/AU2003206924B2/en not_active Expired
- 2003-02-19 PL PL370595A patent/PL226401B1/en unknown
- 2003-02-19 ME MEP-2008-855A patent/ME00566B/en unknown
- 2003-02-19 EA EA200401019A patent/EA008219B1/en active Protection Beyond IP Right Term
- 2003-02-19 ES ES10173234T patent/ES2424634T3/en not_active Expired - Lifetime
- 2003-02-19 US US10/505,138 patent/US7951397B2/en not_active Expired - Lifetime
- 2003-02-19 CA CA2475923A patent/CA2475923C/en not_active Expired - Fee Related
- 2003-02-20 AR ARP030100542A patent/AR038527A1/en not_active Application Discontinuation
-
2004
- 2004-07-02 TN TNP2004000124A patent/TNSN04124A1/en unknown
- 2004-07-04 IL IL162843A patent/IL162843A/en unknown
- 2004-07-09 MA MA27774A patent/MA27100A1/en unknown
- 2004-08-18 IS IS7410A patent/IS7410A/en unknown
- 2004-08-19 EC EC2004005238A patent/ECSP045238A/en unknown
- 2004-11-22 NO NO20043904A patent/NO332844B1/en not_active IP Right Cessation
-
2005
- 2005-11-07 HK HK05109914.9A patent/HK1077752A1/en not_active IP Right Cessation
-
2006
- 2006-08-10 US US11/501,836 patent/US20060269600A1/en not_active Abandoned
-
2010
- 2010-09-07 US US12/876,996 patent/US20110060016A1/en not_active Abandoned
-
2011
- 2011-01-18 US US13/008,842 patent/US8431154B2/en not_active Expired - Lifetime
-
2012
- 2012-05-31 CY CY20121100493T patent/CY1112811T1/en unknown
-
2013
- 2013-01-11 US US13/739,457 patent/US20130131123A1/en not_active Abandoned
- 2013-04-30 US US13/874,065 patent/US9468598B2/en not_active Expired - Lifetime
- 2013-07-31 CY CY20131100654T patent/CY1114210T1/en unknown
- 2013-09-26 US US14/038,666 patent/US20140031396A1/en not_active Abandoned
- 2013-09-26 US US14/038,678 patent/US20140031397A1/en not_active Abandoned
-
2015
- 2015-02-12 IL IL237196A patent/IL237196A0/en unknown
- 2015-06-05 US US14/731,964 patent/US20150290178A1/en not_active Abandoned
- 2015-06-09 US US14/735,015 patent/US20150290180A1/en not_active Abandoned
- 2015-06-09 US US14/735,004 patent/US20150290179A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340827A (en) * | 1992-06-15 | 1994-08-23 | Celltech, Limited | Phenylcarboxamide compounds which have useful pharmaceutical activity |
US6218400B1 (en) * | 1995-07-14 | 2001-04-17 | Icos Corporation | Treatment method using a cGMP-Specific PDE inhibitor |
EP1120120A1 (en) * | 1998-10-05 | 2001-08-01 | Eisai Co., Ltd. | Tablets immediately disintegrating in the oral cavity |
US6348602B1 (en) * | 1999-12-23 | 2002-02-19 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
WO2002045693A1 (en) * | 2000-12-07 | 2002-06-13 | Altana Pharma Ag | Pharmaceutical preparation comprising an active dispersed on a matrix |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9468598B2 (en) | 2002-02-20 | 2016-10-18 | Astrazeneca Ab | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
US8431154B2 (en) | 2002-02-20 | 2013-04-30 | Takeda Gmbh | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
US7951397B2 (en) | 2002-02-20 | 2011-05-31 | Nycomed Gmbh | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
US8536206B2 (en) | 2003-03-08 | 2013-09-17 | Takeda Gmbh | Process for the preparation of roflumilast |
WO2004080967A1 (en) | 2003-03-10 | 2004-09-23 | Altana Pharma Ag | Novel process for the preparation of roflumilast |
US7470791B2 (en) | 2003-03-10 | 2008-12-30 | Nycomed Gmbh | Process for the preparation of roflumilast |
JP2011126912A (en) * | 2003-05-08 | 2011-06-30 | Nycomed Gmbh | Dosage form containing pantoprazole as active ingredient |
WO2004103407A2 (en) | 2003-05-22 | 2004-12-02 | Altana Pharma Ag | Composition comprising a pde4 inhibitor and a pde5 inhibitor |
WO2005041855A3 (en) * | 2003-10-29 | 2007-05-10 | Boehringer Ingelheim Int | Pharmaceutical formulation containing an ltb4 antagonist, method for the production thereof, and use thereof |
JP2007513068A (en) * | 2003-10-29 | 2007-05-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pharmaceutical formulations containing LTB4-antagonists, methods for their preparation and their use |
WO2005041855A2 (en) * | 2003-10-29 | 2005-05-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation containing an ltb4 antagonist, method for the production thereof, and use thereof |
ES2245891A1 (en) * | 2004-07-09 | 2006-01-16 | Clinmet S.L. | Formation of a universal excipient for oral pharmaceuticals administration consists of incorporation of aqueous solution in the active principal of the pharmaceutical |
US9205044B2 (en) * | 2004-09-22 | 2015-12-08 | Takeda Gmbh | Aqueous pharmaceutical preparation comprising roflumilast |
US8663694B2 (en) | 2005-03-16 | 2014-03-04 | Takeda Gmbh | Taste masked dosage form containing roflumilast |
EP2258350A3 (en) * | 2005-03-16 | 2012-08-15 | Nycomed GmbH | Taste masked dosage form containing roflumilast |
EP2258350A2 (en) | 2005-03-16 | 2010-12-08 | Nycomed GmbH | Taste masked dosage form containing roflumilast |
WO2006097456A1 (en) * | 2005-03-16 | 2006-09-21 | Nycomed Gmbh | Taste masked dosage form containing roflumilast |
JP2008533089A (en) * | 2005-03-16 | 2008-08-21 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | A tasted dosage form containing roflumilast |
US8648100B2 (en) | 2005-04-19 | 2014-02-11 | Takeda Gmbh | Roflumilast for the treatment of pulmonary hypertension |
WO2006111495A1 (en) * | 2005-04-19 | 2006-10-26 | Nycomed Gmbh | Roflumilast for the treatment of pulmonary hypertension |
EP2366393A2 (en) | 2005-04-19 | 2011-09-21 | Nycomed GmbH | Roflumilast for the treatment of pulmonary hypertension |
EA016037B1 (en) * | 2005-04-19 | 2012-01-30 | Никомед Гмбх | Roflumilast for the treatment of pulmonary hypertension |
EP2359826A1 (en) | 2006-07-05 | 2011-08-24 | Nycomed GmbH | Combination of HMG-COA reductase inhibitors, such as roflumilast, roflumilast-N-oxide with a phosphodiesterase 4 inhibitor, rosuvastatin, for the treatment of inflammatory pulmonary diseases |
EP2363130A1 (en) | 2006-07-05 | 2011-09-07 | Nycomed GmbH | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases |
US9713614B2 (en) | 2006-07-05 | 2017-07-25 | Astrazeneca Ab | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases |
WO2008093221A3 (en) * | 2007-02-01 | 2008-10-16 | Glenmark Pharmaceuticals Sa | Pharmaceutical compositions containing pde4 inhibitor for the treatment of inflammatory and allergic disorders |
WO2008093221A2 (en) * | 2007-02-01 | 2008-08-07 | Glenmark Pharmaceuticals, S.A. | Pharmaceutical compositions containing pde4 inhibitor for the treatment of inflammatory and allergic disorders |
US9707296B2 (en) | 2007-03-29 | 2017-07-18 | Daiichi Sankyo Company, Limited | Pharmaceutical composition |
US9149532B2 (en) * | 2007-03-29 | 2015-10-06 | Daiichi Sanykyo Company, Limited | Pharmaceutical composition |
EP2186521A1 (en) * | 2008-11-14 | 2010-05-19 | Mergemeier Steffen | Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound |
WO2010054858A2 (en) * | 2008-11-14 | 2010-05-20 | Steffen Mergemeier | Polyvinylpyrrolidone as a therapeutically active compound for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens |
WO2010054858A3 (en) * | 2008-11-14 | 2010-08-19 | Steffen Mergemeier | Polyvinylpyrrolidone as a therapeutically active compound for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens |
US9918975B2 (en) | 2010-03-19 | 2018-03-20 | Daiichi Sankyo Company, Limited | Method for improving dissolution of anticoagulant agent |
US9504663B2 (en) | 2011-02-07 | 2016-11-29 | Scipharm Sarl | Composition for the treatment of cystic fibrosis |
US9402907B2 (en) | 2011-08-10 | 2016-08-02 | Daiichi Sankyo Company, Limited | Pharmaceutical composition containing diamine derivative |
CN103330689A (en) * | 2013-03-31 | 2013-10-02 | 北京万全德众医药生物技术有限公司 | Orally disintegrating tablet comprising roflumilast |
WO2016016824A1 (en) | 2014-07-29 | 2016-02-04 | Fundacio Hospital Universitari Vall D' Hebron-Institut De Recerca | Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis |
WO2016120746A1 (en) * | 2015-01-29 | 2016-08-04 | Micro Labs Limited | A pharmaceutical composition comprising roflumilast |
RU2659206C2 (en) * | 2016-04-14 | 2018-06-28 | Общество с ограниченной ответственностью "Технофарм" | Composition and method for industrial production of digoxin trituration (options) |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9468598B2 (en) | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient | |
JP5383183B2 (en) | A tasted dosage form containing roflumilast | |
KR100930329B1 (en) | Improved Formulation of 6-mercaptopurine | |
ZA200406644B (en) | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyroolidone as excipient | |
EP3843702B1 (en) | Immediate release fixed-dose combination of memantine and donepezil | |
DE10207160A1 (en) | Dosage form useful for treating diseases e.g. psoriasis, allergic contact eczema, atopic eczema, sunburn and pruritis comprises phosphodiesterase inhibitor and polyvinylpyrrolidone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-736/04 Country of ref document: YU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003704652 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AU BA BR CA CN CO CU DZ EC GE HR ID IL IN IS JP KR LT LV MA MK MX NO NZ PH PL RO SG TN UA US VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/A/2004/005759 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 162843 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 369/MUMNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003569234 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2475923 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2004-501237 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/06644 Country of ref document: ZA Ref document number: 20038042304 Country of ref document: CN Ref document number: 10505138 Country of ref document: US Ref document number: 200406644 Country of ref document: ZA Ref document number: 1020047012904 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200401019 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 535197 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003206924 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: GE Ref document number: GE P |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200400934 Country of ref document: VN Ref document number: 8411 Country of ref document: GE |
|
WWP | Wipo information: published in national office |
Ref document number: 2003704652 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020107019428 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 237196 Country of ref document: IL |